Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Van Cutsem E, et al. Among authors: constenla m. J Clin Oncol. 2006 Nov 1;24(31):4991-7. doi: 10.1200/JCO.2006.06.8429. J Clin Oncol. 2006. PMID: 17075117 Clinical Trial.
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E; V-325 Study Group. Ajani JA, et al. Among authors: constenla m. J Clin Oncol. 2007 Aug 1;25(22):3205-9. doi: 10.1200/JCO.2006.10.4968. J Clin Oncol. 2007. PMID: 17664467 Clinical Trial.
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E; V-325 Study Group. Ajani JA, et al. Among authors: constenla m. J Clin Oncol. 2007 Aug 1;25(22):3210-6. doi: 10.1200/JCO.2006.08.3956. J Clin Oncol. 2007. PMID: 17664468 Clinical Trial.
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M. Rosell R, et al. Among authors: constenla m. Ann Oncol. 2008 Feb;19(2):362-9. doi: 10.1093/annonc/mdm474. Epub 2007 Oct 17. Ann Oncol. 2008. PMID: 17947225 Free article. Clinical Trial.
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
Aranda E, Valladares M, Martinez-Villacampa M, Benavides M, Gomez A, Massutti B, Marcuello E, Constenla M, Cámara JC, Carrato A, Dueñas R, Reboredo M, Navarro M, Díaz-Rubio E. Aranda E, et al. Among authors: constenla m. Ann Oncol. 2009 Feb;20(2):251-7. doi: 10.1093/annonc/mdn557. Epub 2008 Aug 20. Ann Oncol. 2009. PMID: 18718892 Free article. Clinical Trial.
Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary.
Provencio M, Sánchez A, Artal A, Sánchez Torres JM, García Gómez R, Constenla M, de Castro J, Dómine M, Viñolas N, Sánchez A, Pérez FJ. Provencio M, et al. Among authors: constenla m. Clin Transl Oncol. 2013 Aug;15(8):659-64. doi: 10.1007/s12094-012-0989-6. Epub 2013 Jan 29. Clin Transl Oncol. 2013. PMID: 23359178
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Casal J, et al. Among authors: constenla m. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. doi: 10.1007/s00280-007-0418-7. Epub 2007 Feb 2. Cancer Chemother Pharmacol. 2007. PMID: 17273825 Clinical Trial.
78 results